Applied Biosystems to invest in VisiGen Biotechnologies Inc.

06-Jan-2006

Applied Biosystems has agreed to invest in, and collaborate with, VisiGen Biotechnologies, Inc. VisiGen's technological approach to DNA sequencing is based on the ability to analyse a single molecule of DNA in real time, which has the potential to drastically reduce the cost of sequencing and significantly improve throughput compared to existing commercially available technologies. Their solution could provide a quantum leap in the scope and scale of research aimed at uncovering the genetic basis of common diseases such as cancer, heart disease and diabetes.

"Applied Biosystems continues to extensively evaluate potential next-generation sequencing technologies. We believe that the quality of VisiGen's science and the progress towards the development of single-molecule sequencing technology is quite impressive," explained Catherine M. Burzik, President of Applied Biosystems.

Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance